We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

75 hedge funds and large institutions have $494M invested in Epizyme, Inc in 2014 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 32 increasing their positions, 16 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 6

100% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 16

51% more capital invested

Capital invested by funds: $326M → $494M (+$168M)

25% more funds holding

Funds holding: 6075 (+15)

7% more call options, than puts

Call options by funds: $876K | Put options by funds: $815K

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
75
Holders Change
+15
Holders Change %
+25%
% of All Funds
2.17%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
21
Increased
32
Reduced
16
Closed
6
Calls
$876K
Puts
$815K
Net Calls
+$61K
Net Calls Change
+$61K
Name Holding Trade Value Shares
Change
Change in
Stake
NMC
1
NEA Management Company
Maryland
$147M
Fidelity Investments
2
Fidelity Investments
Massachusetts
$85.4M +$53.1M +1,753,226 +88%
MAM
3
MPM Asset Management
Massachusetts
$55M -$14.1M -466,666 -16%
Primecap Management
4
Primecap Management
California
$27M +$28.6M +943,250 +392%
Vanguard Group
5
Vanguard Group
Pennsylvania
$15.6M +$13.1M +430,775 +168%
JP Morgan Chase
6
JP Morgan Chase
New York
$13.5M +$18M +594,241 New
GGHC
7
Gilder Gagnon Howe & Co
New York
$13.1M -$175K -5,763 -1%
BFA
8
BlackRock Fund Advisors
California
$13M +$2.97M +97,947 +21%
QF
9
QVT Financial
New York
$10.9M +$10.7M +352,700 +282%
Citigroup
10
Citigroup
New York
$10.4M +$13.7M +453,490 +8,669%
BA
11
BlackRock Advisors
Delaware
$9.11M +$12M +397,246 +13,656%
Capital World Investors
12
Capital World Investors
California
$8.74M +$8.61M +284,000 +284%
EA
13
Emerald Advisers
Pennsylvania
$6.39M +$8.51M +280,752 New
SCA
14
SAC Capital Advisors
Connecticut
$6.26M +$7.69M +253,830 +1,197%
NI
15
Numeric Investors
Massachusetts
$5.87M +$7.81M +257,574 New
UBS AM
16
UBS AM
Illinois
$5.69M -$313K -10,323 -4%
EMFAT
17
Emerald Mutual Fund Advisers Trust
Pennsylvania
$5.53M +$4.11M +135,448 +126%
BBA
18
Baker Bros. Advisors
New York
$4.87M -$182K -5,988 -3%
Wellington Management Group
19
Wellington Management Group
Massachusetts
$4.78M -$533K -17,589 -8%
DCM
20
Driehaus Capital Management
Illinois
$4.52M -$4.84M -159,722 -45%
SM
21
Sabby Management
Florida
$3.44M +$4.58M +151,220 New
QBFM
22
QS Batterymarch Financial Management
New York
$2.75M -$133K -4,400 -4%
OM
23
Opaleye Management
Massachusetts
$2.63M +$3.5M +115,500 New
Lord, Abbett & Co
24
Lord, Abbett & Co
New Jersey
$2.42M -$10.2K -336 -0.3%
State Street
25
State Street
Massachusetts
$2.38M +$768K +25,352 +32%

EPZM Hedge Fund Activity: Q1 2014 in Review

75 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q1 2014, worth a combined $494M — up 51% from $326M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new EPZM positions and 6 closed out — a net gain of 15 holders — while 32 added to existing stakes and 16 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $53.1M. The largest seller was MPM Asset Management, cutting an estimated $14.1M.

  • 75 institutional investors held Epizyme, Inc (EPZM) as of Q1 2014, up from 60 in Q4 2013.
  • Funds reported $494M of Epizyme, Inc stock for Q1 2014, up 51% quarter-over-quarter.
  • 21 funds opened new Epizyme, Inc positions in Q1 2014 and 6 closed out, a net change of +15 holders.
  • The largest Epizyme, Inc buyer in Q1 2014 was Fidelity Investments, an estimated $53.1M added.
  • The largest Epizyme, Inc seller in Q1 2014 was MPM Asset Management, an estimated $14.1M sold.

Based on aggregated 13F filings for Q1 2014.